levodopa and mazindol
levodopa has been researched along with mazindol in 24 studies
Research
Studies (24)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.33) | 18.7374 |
| 1990's | 12 (50.00) | 18.2507 |
| 2000's | 8 (33.33) | 29.6817 |
| 2010's | 2 (8.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Alexander, GM; Brainard, L; Gordon, SW; Grothusen, JR; Schwartzman, RJ | 1 |
| Dworkin, RH; Opler, LA | 1 |
| Blunt, SB; Jenner, P; Marsden, CD | 1 |
| Joyce, JN; Neal, BS | 1 |
| Coakley, JH; Edwards, RH; Griffiths, RD | 1 |
| Betti, RT; Otto, PA; Pavanello, Rde C; Rapaport, D; Rocha, JM; Vainzof, M; Zatz, M | 1 |
| Jenner, P; Jolkkonen, J; Marsden, CD | 1 |
| Casarejos, MJ; De Yébenes, JG; Mena, MA; Paíno, CL; Pardo, B | 1 |
| Ikawa, K; Kaneno, S; Toru, M; Watanabe, A | 1 |
| Gnanalingham, KK; Robertson, RG | 1 |
| Bonnet, JJ; Costentin, J; Thibaut, F; Vaugeois, JM | 1 |
| Hashitani, T; Kumazaki, M; Mizukawa, K; Nishino, H | 1 |
| Brotchie, JM; Crossman, AR; Henry, B | 2 |
| Cannizzaro, C; Costa, S; Iravani, MM; Jackson, MJ; Jenner, P; Pearce, RK; Tel, BC | 1 |
| Halliwell, B; Jenner, P; Lyras, L; McKenzie, G; Pearce, RK; Zeng, BY | 1 |
| Fekete, MI; Fülöp, F; Homicskó, KG; Kertész, I; Nagy, GM; Radnai, B; Tóth, BE; Tóth, G | 1 |
| Cannizzaro, C; Jenner, P; Pearce, RK; Rose, S; Tel, BC; Zeng, BY | 1 |
| Nielsen, KM; Soghomonian, JJ | 1 |
| Cenci, MA; Lindgren, H; Lundblad, M; Picconi, B | 1 |
| Soghomonian, JJ | 1 |
| Amalric, M; Baunez, C; Chezaubernard, C; Maurin, B; Morain, P; Nieoullon, A; Puma, C; Turle-Lorenzo, N | 1 |
Other Studies
24 other study(ies) available for levodopa and mazindol
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Brain; Brain Chemistry; Catecholamines; Dopamine; Dopamine Agents; Levodopa; Macaca fascicularis; Male; Mazindol; Parkinson Disease, Secondary; Receptors, Dopamine | 1992 |
Simple schizophrenia, negative symptoms, and prefrontal hypodopaminergia.
Topics: Dopamine; Frontal Lobe; Humans; Levodopa; Mazindol; Schizophrenia; Schizophrenic Psychology | 1992 |
The effect of L-dopa and carbidopa treatment on the survival of rat fetal dopamine grafts assessed by tyrosine hydroxylase immunohistochemistry and [3H]mazindol autoradiography.
Topics: Animals; Autoradiography; Brain Tissue Transplantation; Carbidopa; Dopamine; Female; Fetal Tissue Transplantation; Graft Survival; Immunohistochemistry; Levodopa; Mazindol; Rats; Rats, Inbred Strains; Tyrosine 3-Monooxygenase | 1991 |
Dopamine D1 receptor behavioral responsitivity following selective lesions of the striatal patch compartment during development.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Aging; Analysis of Variance; Animals; Animals, Newborn; Apomorphine; Autoradiography; Corpus Striatum; Haloperidol; Hydroxydopamines; Levodopa; Mazindol; Motor Activity; Neurotoxins; Oxidopamine; Rats; Rats, Inbred Strains; Receptors, Dopamine; Receptors, Dopamine D1; Stereotyped Behavior; Tritium | 1991 |
Height and clinical course of Duchenne muscular dystrophy.
Topics: Body Height; Data Interpretation, Statistical; Growth Hormone; Humans; Levodopa; Longitudinal Studies; Male; Mazindol; Muscular Dystrophies | 1989 |
Effect of mazindol on growth hormone levels in patients with Duchenne muscular dystrophy.
Topics: Adolescent; Child; Child, Preschool; Growth Hormone; Humans; Indoles; Levodopa; Male; Mazindol; Muscular Dystrophies | 1988 |
L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Autoradiography; Callithrix; Caudate Nucleus; Enkephalins; Female; Gene Expression; In Situ Hybridization; Levodopa; Male; Mazindol; Motor Activity; Nucleus Accumbens; Putamen; RNA, Messenger; Substance P | 1995 |
Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants.
Topics: Animals; Antioxidants; Cells, Cultured; Coloring Agents; Dopamine Agents; Dopamine Uptake Inhibitors; Immunohistochemistry; Levodopa; Mazindol; Mesencephalon; Nerve Tissue Proteins; Neurons; Neurotransmitter Agents; Quinones; Rats; Rats, Sprague-Dawley; Time Factors; Trypan Blue | 1995 |
Modulation of [3H]mazindol binding sites in rat striatum by dopaminergic agents.
Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Methyltyrosine; Animals; Binding Sites; Dopamine; Dopamine Agents; Homovanillic Acid; Levodopa; Male; Mazindol; Methyltyrosines; Neostriatum; Neurotransmitter Uptake Inhibitors; Piperazines; Rats; Rats, Wistar; Receptors, Presynaptic; Tyrosine 3-Monooxygenase | 1993 |
The effects of chronic continuous versus intermittent levodopa treatments on striatal and extrastriatal D1 and D2 dopamine receptors and dopamine uptake sites in the 6-hydroxydopamine lesioned rat--an autoradiographic study.
Topics: Animals; Apomorphine; Autoradiography; Behavior, Animal; Benzazepines; Dopamine; Levodopa; Male; Mazindol; Medial Forebrain Bundle; Neostriatum; Oxidopamine; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Stereotyped Behavior; Sulpiride | 1994 |
Pharmacological modifications of dopamine transmission do not influence the striatal in vivo binding of [3H]mazindol or [3H]cocaine in mice.
Topics: 4-Butyrolactone; Analysis of Variance; Animals; Cerebellum; Cocaine; Dextroamphetamine; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; GABA Modulators; Injections, Intravenous; Levodopa; Mazindol; Mice; Neostriatum; Protein Binding; Tritium | 1996 |
Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Autoradiography; Brain Tissue Transplantation; Carrier Proteins; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Female; Fetal Tissue Transplantation; Functional Laterality; Haloperidol; Homovanillic Acid; Kinetics; Levodopa; Mazindol; Membrane Glycoproteins; Membrane Transport Proteins; Mesencephalon; Methamphetamine; Microdialysis; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Wistar; Rotation; Tritium; Tyrosine 3-Monooxygenase | 1998 |
Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Behavior, Animal; Bromocriptine; Clonidine; Disease Models, Animal; Dopamine; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Levodopa; Lisuride; Locomotion; Male; Mazindol; Methoxydimethyltryptamines; Oxidopamine; Parkinson Disease, Secondary; Prosencephalon; Rats; Rats, Sprague-Dawley; Sympatholytics; Tritium; Yohimbine | 1998 |
Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Topics: Animals; Autoradiography; Behavior, Animal; Bromocriptine; Dopamine Agents; Dopamine Agonists; Dopamine Uptake Inhibitors; Enkephalins; In Situ Hybridization; Levodopa; Lisuride; Male; Mazindol; Medial Forebrain Bundle; Neostriatum; Oligonucleotide Probes; Oxidopamine; Parkinson Disease, Secondary; Protein Precursors; Radioligand Assay; Rats; Rats, Sprague-Dawley; RNA, Messenger | 1999 |
GDNF reverses priming for dyskinesia in MPTP-treated, L-DOPA-primed common marmosets.
Topics: Animals; Antiparkinson Agents; Body Weight; Callithrix; Corpus Striatum; Disease Models, Animal; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Enkephalins; Female; Gene Expression; Glial Cell Line-Derived Neurotrophic Factor; Levodopa; Locomotion; Male; Mazindol; MPTP Poisoning; Nerve Growth Factors; Nerve Tissue Proteins; Neuroprotective Agents; Protein Precursors; Recovery of Function; RNA, Messenger; Substantia Nigra; Tachykinins; Tritium; Tyrosine 3-Monooxygenase | 2001 |
Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
Topics: Animals; Antiparkinson Agents; Carbidopa; Catechol O-Methyltransferase Inhibitors; Catechols; Cerebral Cortex; Corpus Striatum; DNA Damage; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Levodopa; Macaca fascicularis; Mazindol; Neural Pathways; Nitriles; Oxidative Stress; Reference Values; RNA, Messenger; Substantia Nigra; Tyrosine 3-Monooxygenase | 2002 |
Binding site of salsolinol: its properties in different regions of the brain and the pituitary gland of the rat.
Topics: Animals; Aromatic Amino Acid Decarboxylase Inhibitors; Aromatic-L-Amino-Acid Decarboxylases; Benserazide; Binding Sites; Binding, Competitive; Brain; Carbidopa; Clonidine; Corpus Striatum; Dopamine; Dopamine Agonists; Dopamine Antagonists; Enzyme Inhibitors; Female; Isoquinolines; Kinetics; Lactation; Levodopa; Male; Mazindol; Median Eminence; Methyldopa; Pituitary Gland; Pituitary Gland, Posterior; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine; Reserpine | 2003 |
Alterations in striatal neuropeptide mRNA produced by repeated administration of L-DOPA, ropinirole or bromocriptine correlate with dyskinesia induction in MPTP-treated common marmosets.
Topics: Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dopamine Uptake Inhibitors; Dyskinesia, Drug-Induced; Enkephalins; Female; Indoles; Levodopa; Male; Mazindol; Neostriatum; Neural Pathways; Neuropeptides; Parkinsonian Disorders; Protein Precursors; Receptors, Purinergic P1; RNA, Messenger; Tachykinins | 2002 |
Dual effects of intermittent or continuous L-DOPA administration on gene expression in the globus pallidus and subthalamic nucleus of adult rats with a unilateral 6-OHDA lesion.
Topics: Animals; Autoradiography; Behavior, Animal; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Electron Transport Complex IV; Gene Expression Regulation; Gene Expression Regulation, Enzymologic; Globus Pallidus; Glutamate Decarboxylase; In Situ Hybridization; Isoenzymes; Levodopa; Male; Mazindol; Neurons; Oxidopamine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; RNA, Messenger; Substantia Nigra; Subthalamic Nucleus | 2003 |
A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function.
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Mazindol; Mice; Mice, Inbred C57BL; Motor Skills; Oxidopamine; Protein Binding; Substantia Nigra | 2004 |
L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus.
Topics: Animals; Autoradiography; Behavior, Animal; Dopamine; Dopamine Agents; Dopamine Uptake Inhibitors; Dyskinesias; Functional Laterality; Gene Expression; Immunohistochemistry; In Situ Hybridization; Levodopa; Male; Mazindol; Neurons; Oxidopamine; Proto-Oncogene Proteins c-fos; Rats; Rats, Sprague-Dawley; Substantia Nigra; Subthalamic Nucleus; Time Factors; Tritium | 2006 |
The dopamine agonist piribedil with L-DOPA improves attentional dysfunction: relevance for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Attention Deficit Disorder with Hyperactivity; Cognition; Corpus Striatum; Dopamine Agonists; Drug Therapy, Combination; Levodopa; Male; Mazindol; Motor Activity; Parkinson Disease; Piribedil; Rats; Rats, Wistar; Reaction Time | 2006 |